Assessment of Price Changes of Existing Tumor Necrosis Factor Inhibitors after the Market Entry of Competitors

JAMA Internal Medicine

Volumn 179, Issue 5, 2019, Pages 713-716

  San Juan Rodriguez, Alvaro ^a   Prokopovich, Max V ^a,b   Shrank, William H ^b   Good, Chester B ^b   Hernandez, Inmaculada ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR INHIBITOR;

DRUG COST; DRUG MARKETING; HUMAN; LETTER; MEDICARE; PRIORITY JOURNAL;

EID: 85061641653     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2018.7656     Document Type: Letter

References (5)

1. Mazumdar S, Greenwald D. Golimumab. MAbs. 2009; 1 (5): 422-431. doi: 10.4161/mabs.1.5.9286 20065639
2. Goel N, Stephens S. Certolizumab pegol. MAbs. 2010; 2 (2): 137-147. doi: 10.4161/mabs.2.2.11271 20190560
3. Brady BL, Tkacz JP, Lofland J, Meyer R, Bolge SC. Prescribing patterns of intravenous golimumab for rheumatoid arthritis. Clin Ther. 2015; 37 (9): 2028-2036. doi: 10.1016/j.clinthera.2015.06.017 26210073
4. First Databank. AnalySource premier drug pricing services. https://www.fdbhealth.com/solutions/analysource-premier-drug-pricing-services/. Accessed April 13, 2018.
5. Centers for Medicare & Medicaid Services. 2017 Annual report of the board of trustees of the Federal Hospital Insurance and Federal Supplementary Medical Insurance Trust Funds. https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/ReportsTrustFunds/Downloads/TR2017.pdf. Accessed May 7, 2018.